Wire · opportunities
Trastuzumab Botidotin Shows 11.1-Month PFS vs T-DM1 in Phase 3 Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
Trastuzumab botidotin demonstrated a median progression-free survival of 11.1 months compared to 4.4 months for T-DM1 in a Phase 3 trial for HER2-positive breast cancer, with improved response rates and manageable safety profile. The drug is approved in China and is being further studied for sequencing after topoisomerase inhibitor ADCs.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must update your breast cancer drug strategy to include trastuzumab botidotin as a new benchmark for efficacy and safety in HER2-positive second-line treatment. Pay close attention to upcoming Phase 2 data on sequencing after other ADCs to capture evolving market opportunities.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics